الفهرس 
Solvent emulsification diffusion methodOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Large number of the pharmacologically active drug candidates are categorized as class IV drugs according to the biopharmaceutical categorization system (BCS). Unfortunately, this class of drugs presents an even greater challenge because their absorption is restricted by both their poor aqueous solubility in the aqueous environment of the gastrointestinal tract and their limited permeability. So, it is a monumental task for any formulator to develop a BCS class IV drug formulation with an effective delivery method. Solid lipid nanoparticles (SLnPs) are one of the utilized lipid-based formulations for enhancing oral bioavailability of BCS class IV drugs. Because they can enhance gastrointestinal solubilization and absorption by targeted lymphatic uptake of insufficiently bioavailable medications, lipids as carriers have the capability to open up countless prospects in the field of drug administration. This could be explained by some special characteristics of lipids, like their high solubilizing ability, industrial scalability, biocompatibility, and discrete route of absorption, which remove many physiological barriers, like pre-systemic metabolism, gastrointestinal degradation, P-gp efflux, and permeability-related issues. Apixaban (APX) is a model of class IV drugs. It is a potent anticoagulant that when administered orally inhibits the coagulation factor Xa selectively and directly. So, apixaban is frequently used as a preventive treatment for the avoidance of venous thromboembolism. Accordingly, this work aimed to investigate the effect of formulation and processing variables on the properties of the developed SLnPs for oral delivery of apixaban.